Gilead Sciences, Inc. (GILD) Shares Bought by YHB Investment Advisors Inc.
YHB Investment Advisors Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,068 shares of the biopharmaceutical company’s stock after purchasing an additional 6,609 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Gilead Sciences were worth $2,624,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its holdings in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC increased its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. increased its holdings in Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the 1st quarter valued at about $143,000. 73.99% of the stock is currently owned by institutional investors.
Several equities analysts have recently issued reports on GILD shares. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Royal Bank Of Canada assumed coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target for the company. Robert W. Baird restated an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Eleven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $84.29.
In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders sold 388,486 shares of company stock valued at $31,178,297 in the last ninety days. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.19 on Wednesday. The stock has a market capitalization of $108.64 billion, a P/E ratio of 9.04 and a beta of 1.14. The company’s 50 day moving average price is $80.13 and its 200 day moving average price is $71.40. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.08 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.78 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.